Search results for "Antineoplastic"

showing 10 items of 2217 documents

Progestogens reduce thromboxane production by cultured human endothelial cells.

2011

Objectives Progestogens have been poorly studied concerning their roles in endothelial physiology. Prostanoids are vasoactive compounds, such as thromboxane A2, a potent vasoconstrictor, and prostacyclin, a vasodilator. We examined the effects of two progestogens used clinically, progesterone and medroxyprogesterone acetate, on thromboxane A2 production by cultured human umbilical vein endothelial cells (HUVEC) and investigated the role of progesterone receptors and the enzymes involved in production of thromboxane A2 and prostacyclin. Methods Cells were exposed to 1‐100 nmol/l of either progesterone or medroxyprogesterone acetate, and thromboxane A2 production was measured in culture mediu…

medicine.medical_specialtyUmbilical VeinsAntineoplastic Agents HormonalThromboxaneBlotting WesternGene ExpressionProstacyclinMedroxyprogesterone AcetatePolymerase Chain ReactionProstacyclin synthaseThromboxane receptorThromboxane ProductionThromboxane A2chemistry.chemical_compoundThromboxane A2Hormone AntagonistsCytochrome P-450 Enzyme SystemInternal medicineProgesterone receptorMedicineHumansCyclooxygenase InhibitorsRNA MessengerCells CulturedProgesteronebiologyDose-Response Relationship Drugbusiness.industryObstetrics and GynecologyEndothelial CellsGeneral MedicineIntramolecular OxidoreductasesThromboxane B2MifepristoneEndocrinologychemistrycardiovascular systembiology.proteinPyrazolesThromboxane-A synthaseThromboxane-A SynthaseProgestinsbusinessmedicine.drugClimacteric : the journal of the International Menopause Society
researchProduct

Results of conservative treatment (transurethral resection plus adjuvant intravesical chemotherapy) in patients with primary T1, G3 transitional cell…

1996

Objectives. To evaluate a selected population of 50 consecutive patients with primary T1, G3 bladder transitional cell carcinoma in the absence of carcinoma in situ (Tis) treated with a bladder-sparing approach. Methods. Between January 1983 and December 1992, all patients were treated by transurethral resection (TUR) plus adjuvant intravesical chemotherapy over 1 year. In most cases, doxorubicin, epirubicin, and mitomycin were used alone or in combination. Results. At a mean follow-up period of 52 months (range, 18 to 126), 16 of 50 patients (32%) showed a recurrent superficial tumor. The recurrent lesion was of Stage T1 in 11 (22%) cases, but was a T1, G3 tumor only in 5 cases (10%). In 2…

medicine.medical_specialtyUrologymedicine.medical_treatmentPopulationAntineoplastic AgentsMitomycinsSettore MED/24 - UrologiaCystectomyUrethraCarcinomamedicineHumansBACILLUS CALMETTE-GUERINeducationEpirubicinNeoplasm StagingCarcinoma Transitional Celleducation.field_of_studyUrinary bladderBladder cancerbusiness.industryCarcinoma in situmedicine.diseaseCombined Modality TherapyCANCERSurgeryAdministration Intravesicalmedicine.anatomical_structureTransitional cell carcinomaUrinary Bladder NeoplasmsChemotherapy AdjuvantDoxorubicinSurgical Procedures OperativeNeoplasm Recurrence LocalbusinessFollow-Up StudiesEpirubicinmedicine.drugUrology
researchProduct

ICUD-EAU International Consultation on Bladder Cancer 2012: Non–Muscle-Invasive Urothelial Carcinoma of the Bladder

2012

Item does not contain fulltext CONTEXT: Our aim was to present a summary of the Second International Consultation on Bladder Cancer recommendations on the diagnosis and treatment options for non-muscle-invasive urothelial cancer of the bladder (NMIBC) using an evidence-based approach. OBJECTIVE: To critically review the recent data on the management of NMIBC to arrive at a general consensus. EVIDENCE ACQUISITION: A detailed Medline analysis was performed for original articles addressing the treatment of NMIBC with regard to diagnosis, surgery, intravesical chemotherapy, and follow-up. Proceedings from the last 5 yr of major conferences were also searched. EVIDENCE SYNTHESIS: The major findi…

medicine.medical_specialtyUrologymedicine.medical_treatmentUrologyMEDLINEAntineoplastic AgentsContext (language use)Aetiology screening and detection [ONCOL 5]CystectomyQuality of Care [ONCOL 4]Molecular epidemiology [NCEBP 1]CystectomyTranslational research [ONCOL 3]medicineHumansNeoplasm InvasivenessProspective cohort studyNeoplasm StagingBladder cancermedicine.diagnostic_testbusiness.industryGeneral surgeryCarcinoma in situCystoscopymedicine.diseaseAdministration IntravesicalTreatment OutcomeUrinary Bladder NeoplasmsBCG VaccineDisease ProgressionNeoplasm GradingNeoplasm Recurrence LocalUrotheliumbusinessIntravesical chemotherapyCarcinoma in SituEuropean Urology
researchProduct

Treatment of early childhood medulloblastoma by postoperative chemotherapy alone.

2005

The prognosis for young children with medulloblastoma is poor, and survivors are at high risk for cognitive deficits. We conducted a trial of the treatment of this brain tumor by intensive postoperative chemotherapy alone.After surgery, children received three cycles of intravenous chemotherapy (cyclophosphamide, vincristine, methotrexate, carboplatin, and etoposide) and intraventricular methotrexate. Treatment was terminated if a complete remission was achieved. Leukoencephalopathy and cognitive deficits were evaluated.Forty-three children were treated according to protocol. In children who had complete resection (17 patients), residual tumor (14), and macroscopic metastases (12), the five…

medicine.medical_specialtyVincristineCyclophosphamidemedicine.medical_treatmentIntelligenceBrain tumorNeuropsychological TestsCarboplatinchemistry.chemical_compoundAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansCerebellar NeoplasmsCyclophosphamideEtoposideEtoposideProportional Hazards ModelsMedulloblastomaPostoperative CareChemotherapyAnalysis of Variancebusiness.industryDesmoplastic medulloblastomaRemission InductionInfantGeneral Medicinemedicine.diseaseSurvival AnalysisCarboplatinSurgeryMethotrexatechemistryChemotherapy AdjuvantVincristineChild PreschoolNeoplasm Recurrence Localbusinessmedicine.drugFollow-Up StudiesMedulloblastomaThe New England journal of medicine
researchProduct

Absorption of drugs from the bladder and intravesical chemotherapy

1976

medicine.medical_specialtybusiness.industryUrologyUrinary BladderUrologyAntineoplastic AgentsPharmaceutical PreparationsUrinary Bladder NeoplasmsInjections IntravenousAnimalsHumansMedicineRabbitsIntravesical chemotherapybusinessAbsorption (electromagnetic radiation)ThiotepaUrological Research
researchProduct

Glutathione, GlutathioneS-Transferase α and π, and Aldehyde Dehydrogenase Content in Relationship to Drug Resistance in Ovarian Cancer

1997

Glutathione, glutathione S-transferases alpha and pi, and aldehyde dehydrogenase are associated with resistance to carboplatin and/or cyclophosphamide in cell lines. Therefore, we examined whether the expression of these factors in ovarian cancer tissue specimens is associated with resistance of the patients to combination chemotherapy with cyclophosphamide/carboplatin. Ovarian cancer tissue specimens were taken intraoperatively from 139 patients and frozen in liquid nitrogen, and the contents of glutathione S-transferases alpha and pi, total glutathione, and aldehyde dehydrogenase activity were determined. No association between the levels of glutathione S-transferases alpha and pi or alde…

medicine.medical_specialtyendocrine system diseasesCyclophosphamidemedicine.medical_treatmentBlotting WesternAldehyde dehydrogenaseAntineoplastic AgentsOvaryCarboplatinchemistry.chemical_compoundInternal medicineHumansMedicineAntineoplastic Agents AlkylatingCyclophosphamideGlutathione TransferaseNeoplasm StagingOvarian NeoplasmsChemotherapybiologybusiness.industryObstetrics and GynecologyCombination chemotherapyGlutathioneAldehyde DehydrogenasePrognosismedicine.diseaseCombined Modality TherapyGlutathioneDrug Resistance Multiplefemale genital diseases and pregnancy complicationsCarboplatinmedicine.anatomical_structureEndocrinologyOncologychemistryDrug Resistance Neoplasmbiology.proteinCancer researchDrug Therapy CombinationFemaleCisplatinbusinessOvarian cancermedicine.drugGynecologic Oncology
researchProduct

Usefulness of Stress Echocardiography in the Management of Patients Treated with Anticancer Drugs.

2021

In recent years, the survival of patients with cancer has improved thanks to advances in antineoplastic therapeutic protocols. This has led to an increasing burden of cardiovascular complications related to cancer treatment. Therefore, a new branch of cardiology has been created, ``cardio-oncology,'' with the aims of preventing cardiovascular complications related to antineoplastic treatment, achieving early diagnosis and treatment of any complications, and allowing completion of the expected antineoplastic treatment. Stress echocardiography has a pivotal role in achieving a timely diagnosis of coronary artery disease and thus is the best management approach in this clinical setting. Athero…

medicine.medical_specialtymedicine.medical_treatmentAntineoplastic Agents030204 cardiovascular system & hematologyCoronary artery disease030218 nuclear medicine & medical imagingCoronary artery diseaseAntineoplastic Agent03 medical and health sciences0302 clinical medicineAntineoplastic therapeutic protocolsEchocardiography StreNeoplasmsAntineoplastic therapeutic protocolmedicineStress EchocardiographyHumansRadiology Nuclear Medicine and imagingIn patientCADIntensive care medicineAntineoplastic therapeutic protocols CAD Cardio-oncology Cardiotoxicity Coronary artery disease Stress echocardiography Cardiotoxicity Early Detection of Cancer Echocardiography Echocardiography Stress Humans Antineoplastic Agents NeoplasmsEarly Detection of CancerSubclinical infectionChemotherapyCardiotoxicitybusiness.industryCancerAntineoplastic therapeutic protocols; CAD; Cardio-oncology; Cardiotoxicity; Coronary artery disease; Stress echocardiographymedicine.diseaseCardiotoxicityCardio-oncologyStress echocardiographyAnticancer treatmentEchocardiographyCardiology and Cardiovascular MedicinebusinessHumanEchocardiography StressJournal of the American Society of Echocardiography : official publication of the American Society of Echocardiography
researchProduct

Recent clinical evidence on metronomic dosing in controlled clinical trials: a systematic literature review.

2020

Introduction: Metronomic dosing is used to give continuous chemotherapy at low doses. The low doses have minimal side effects and may enable cancer treatment to be remodeled toward the management o...

medicine.medical_specialtymedicine.medical_treatmentAntineoplastic Agents030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineClinical Trials Phase II as TopicNeoplasmsAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansRadiology Nuclear Medicine and imagingDosingIntensive care medicineRandomized Controlled Trials as TopicChemotherapybusiness.industryLow doseHematologyGeneral MedicineProgression-Free SurvivalCancer treatmentClinical trialSurvival RateSystematic reviewOncologyClinical Trials Phase III as TopicClinical evidence030220 oncology & carcinogenesisAdministration MetronomicbusinessActa oncologica (Stockholm, Sweden)
researchProduct

Osteoblastic osteogenic sarcoma in a 13-month-old girl.

1994

Summary Osteosarcoma is exceptional in early periods of life. Therefore osteosarcomas involvingthe bones of the hand are extremely rare. We present a case of an osteogenic sarcoma involving the second metacarpal bone of a 13-month-old girl who has been remaining free of disease, after treatment — radial amputation and chemotherapy pre- and post-operative-, for a period of 10 years in the follow-up.

medicine.medical_specialtymedicine.medical_treatmentmedia_common.quotation_subjectSecond metacarpal boneAmputation SurgicalPathology and Forensic MedicineFingersAntineoplastic Combined Chemotherapy Protocolsmedicinemedicine.boneHumansGirlmedia_commonChemotherapyOsteosarcomabusiness.industryInfantCell Biologymedicine.diseaseCombined Modality TherapySurgeryRadiographyAmputationOsteosarcomaFemaleSarcomaMetacarpusbusinessAfter treatmentFollow-Up StudiesPathology, research and practice
researchProduct

Dendritic cell activation by combined exposure to anti-CD40 plus interleukin (IL)-12 and IL-18 efficiently stimulates anti-tumor immunity

2008

Despite as yet limited clinical effectiveness, dendritic cell (DC)-based immunotherapy remains a promising approach for the treatment of cancer, but requires further improvement in its immunostimulatory effectiveness. Potent anti-tumor immunity often depends on the induction of type 1 (T(H)1) immune responses. Therefore, we combined different DC maturation stimuli that are known to induce T(H)1 immunity [anti-CD40, interleukin (IL)-12, IL-18], with the aim to trigger a T(H)1 driven anti-tumor CTL response. When compared with untreated DC or DC treated with anti-CD40 alone, DC matured with anti-CD40 plus IL-12 and IL-18 expressed significantly more IFN-gamma and IL-12, induced enhanced CD8(+…

medicine.medical_treatmentAntineoplastic AgentsDermatologyCD8-Positive T-LymphocytesModels BiologicalBiochemistryMiceImmune systemAntigens NeoplasmmedicineAnimalsCD40 AntigensAntigen-presenting cellMolecular BiologyMice Inbred BALB Cbusiness.industryInterleukin-18InterleukinDendritic CellsImmunotherapyDendritic cellTh1 CellsInterleukin-12Tumor antigenMice Inbred C57BLImmune SystemImmunologyInterleukin 12ImmunotherapybusinessCD8Experimental Dermatology
researchProduct